Biological Activity
Potent, ATP-competitive Aurora kinase inhibitor (IC50 values are 3, 9 and 31 nM for Aurora C, A and B, respectively). Exhibits both in vitro and in vivo activity against human cancer cell lines and tumor xenograft models. Displays additive antiproliferative effects in combination with chemotherapeutics such as carboplatin (Cat. No. 2626), gemcitabine (Cat. No. 3259) and 5-fluorouracil (Cat. No. 3257).
Compound Libraries
SNS 314 mesylate is also offered as part of the Tocriscreen Plus, Tocriscreen Kinase Inhibitor Toolbox II and Tocriscreen Epigenetics Toolbox. Find out more about compound libraries available from Tocris.
Technical Data
| M. Wt | 527.04 |
| Formula | C18H15ClN6OS2.CH3SO3H |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 1146618-41-8 |
| PubChem ID | 24995523 |
| InChI Key | FYCODPVDEFFWSR-UHFFFAOYSA-N |
| Smiles | O=C(NC4=CC(Cl)=CC=C4)NC3=NC=C(S3)CCNC1=NC=NC2=C1SC=C2.CS(=O)(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 52.7 | 100 |
Preparing Stock Solutions
The following data is based on the product molecular weight 527.04. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.9 mL | 9.49 mL | 18.97 mL |
| 5 mM | 0.38 mL | 1.9 mL | 3.79 mL |
| 10 mM | 0.19 mL | 0.95 mL | 1.9 mL |
| 50 mM | 0.04 mL | 0.19 mL | 0.38 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Arbitrario et al (2010) SNS-314, a pan-Aurora kinase inhibitor, shows potent and anti-tumor activity and dosing flexibility in vivo. Cancer Chemother. Pharmacol. 65 707 PMID: 19649632
VanderPorten et al (2009) The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol.Cancer Ther. 8 930 PMID: 19372566
Oslob et al (2008) Discovery of a potent and selective Aurora kinase inhibitor. Bioorg.Med.Chem.Lett. 18 4880 PMID: 18678489
Keywords: SNS 314 mesylate, supplier, SNS314, mesylate, aurora, kinases, inhibitors, inhibits, potent, antiproliferatives, Aurora, Kinases, Aurora, Kinases, Tocris Bioscience
